Corcept Therapeutics will replace Endocrinology President Sean Maduck with Justin Gunn on October 1, while Maduck receives a $57,000 monthly consulting fee. The arrangement matters to investors because Maduck will continue advising executive management during the transition, with his outstanding stock Options continuing to vest under their original schedules.

Key Highlights

  • Maduck’s outstanding stock options will keep vesting under their existing schedules during the consulting term.
  • Either side can end the consulting arrangement with thirty days’ written notice.
  • The agreement initially runs through September 30, 2027, unless terminated earlier.

Corcept Therapeutics Inc (NASDAQ: CORT) is a major pharmaceuticals company. Sean Maduck will leave his position as President of Corcept’s Endocrinology division on October 1, 2026, and Justin Gunn will take over the role. Maduck will remain involved as a senior commercial adviser under a consulting arrangement paying $57,000 per month.

Gunn Takes Over Endocrinology

Maduck informed Corcept’s board of his resignation on September 22, 2026. The company said his departure was not related to any disagreement over operations, financial statements, policies or practices. Gunn will assume his new responsibilities fully on October 1 and join Corcept’s Executive Team.

Advisory Role Supports Handover

The consulting agreement begins on October 1, 2026, and has an initial expiration date of September 30, 2027. Gunn previously built a field sales and Training organisation supporting the launch of Lifyorli, Corcept’s medicine for platinum-resistant ovarian cancer used with nab-paclitaxel. Maduck’s continued service as an adviser is intended to support the changeover, while Corcept thanked him for his contributions and dedication to patients.